NCT07222267
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 19 with changes below. See every version on ClinicalTrials.gov ↗
Notable Enrollment increased: 86 → 186 participants Show 5 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 46 words
- Secondary endpoints: 14 to 12
- Study description expanded, about 234 words
- Study title shortened, about 1 word
- Minor Site details revised at 1 of 32 sites
- Notable Eligibility criteria expanded, about 11 words
- Study sites: 31 to 32
- Secondary endpoints: details revised at 3 of 14 entries
- Minor Study sites: 30 to 31v16
- Minor Study sites: 29 to 30v15
Show 3 earlier versionsHide 3 earlier versions
- Minor Study sites: 27 to 29v14
- Minor Study sites: 25 to 27v13
- Minor Study sites: 23 to 25v12
- Minor Trial sites expanded: 20 → 23 locationsv11
- Minor Trial sites expanded: 12 → 20 locationsv10
- Minor Study sites: 10 to 12v9
- Minor Primary completion date: Apr 30, 2029 to Sep 30, 2029
- Study completion date: Jul 31, 2036 to Jan 13, 2037
- Minor Study sites: 9 to 10v7
- Minor Study sites: 5 to 9v6
- Minor Study sites: 3 to 5v5
- Minor Study sites: 2 to 3v4
- Minor Study sites: 1 to 2v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Dec 2025 to Dec 11, 2025
- Study site revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Sequential cohorts of increasing dose levels of BG-75202 will be evaluated as monotherapy.
Sequential cohorts of increasing dose levels of BG-75202 will be evaluated in combination with an estrogen receptor antagonist.
Participants will receive BG-75202 in combination with an estrogen receptor antagonist.
Participants will receive BG-75202 in combination with a cyclin-dependent kinase 4 (CDK4) inhibitor and an aromatase inhibitor.
Participants will receive BG-75202 in combination with a CDK4 inhibitor and an aromatase inhibitor.
Drugs: BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor
Sites
32 sites in 6 countries
China 11, United States 6, Australia 5, Spain 5, Italy 4, New Zealand 1